News

As Medicare Bridge participation surges, Novo Nordisk’s share of those new patients is drawing attention.

The company sees the latest trial results reinforcing its ambitions to rapidly develop a portfolio of medicines for people with obesity, diabetes and cardiovascular disease.

A surge in U.S.-China transactions is drawing scrutiny in Washington, where some lawmakers are pushing to slow the pace of investment.

Oura Inc. is pitching its U.S. initial public offering to investors, aiming for a fully diluted value of about $15.62 billion as it sizes up demand for consumer tech deals. The smart-ring maker plans to price next week, as markets...

Smart ring maker Oura is seeking a valuation of as much as $15.6 billion in an IPO that could test investor appetite for a new wave of fall listings.

Oura, a smart ring maker, said Monday it launched a US initial public offering of 50 million common

Oura is offering 50 million shares at $40 to $44 each, targeting a fully diluted valuation of $15.62 billion

All three major US stock indexes were up in late-morning trading Monday, as oil prices and Treasury

Oura, the Finnish maker of smart health-tracking rings, disclosed plans on Monday to sell 50 million shares priced between $40 and $44 each in its initial public offering. The offering could raise as much as $2.2 billion and value the company at up to $14.1 billion based on its outstanding...

Investing.com -- Oura is seeking to offer 50 million shares priced between $40 and $44 each, the company disclosed in a Monday SEC filing. The smart ring maker plans to offer 13.5 million shares, while existing stockholders will sell 36.5 million shares.

Shares in the company fell more than 4% as its CEO laid out plans for new blockbuster drugs in the next few years.

The US Department of Health and Human Services will get a portion of the increased revenue if Pfizer Inc. is able to charge higher drug prices abroad, according to newly released documents.

Doctors are exploring whether weight-loss drugs could also treat conditions such as endometriosis and Crohn’s disease.

By Richa Naidu LONDON, Sept 16 (Reuters) - Consumer health company Haleon has achieved growing sales of products to counter side-effects of weight-loss drugs in the United States, the company said,

Investing.com -- Berenberg analyst Kerry Holford upgraded Eli Lilly to buy, raising its price target to $1,400 in a note Tuesday, representing almost 25% upside, as it backs the drugmaker to extend its lead in the fast-growing obesity market.

Pre-Market Stock Futures: Futures are trading lower as we count down to the Federal Reserve meeting and a likely 25-basis-point increase in the Fed funds rate on Wednesday. The same suspects drove today’s selling, and although all the major indices finished the day lower, they all closed well off the lows printed earlier in the […]

As bootleg versions of an experimental drug from Eli Lilly flood the market, regulators are trying to curb supply.

The drugmaker said its new name aims to make it more recognizable to compete in the market for obesity medications.

Novo Nordisk is shortening its name as part of an effort to boost its appeal to consumers in the obesity drug market, where the Danish drugmaker...

Shares of Amgen were recently down more than 9%, putting the biotechnology company on pace for its largest decrease since October 2000. The decline came after Novartis announced a failure of its heart disease drug, pelacarsen, to reduce the risk of cardiovascular events compared with a placebo. The failure, which sent U.S.-traded Novartis shares down 14%, also cast doubt on similar drugs, including Amgen’s investigational treatment olpasiran.

The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions.

The drug giant added to its immunotherapy portfolio.

Lilly also announced that combining its inflammation treatment Taltz with Zepbound delivered lasting improvements in adults with psoriasis or psoriatic arthritis who were obese in two late trials.

Veeva Systems Inc (VEEV) reports $928 million in revenue and best-ever CRM performance, with Veeva Falcon AI gaining traction.

Veeva Systems (NYSE:VEEV) reported fiscal 2027 second-quarter revenue of $928 million and non-GAAP operating income of $416 million, with Chief Executive Officer Peter Gassner saying results exceeded the company’s guidance. Management highlighted record CRM performance, broad commercial-cloud moment

Dow Jones AI giant Nvidia stock is trying to find support at a key level. Nvidia earnings are due Wednesday after the close.

The Food and Drug Administration cleared a blood test for identifying Alzheimer’s disease symptoms, which was developed by Roche and Eli Lilly.

The once-daily pill was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event of at least one weight-related health condition.

By Andrew Silver SHANGHAI, Aug 24 (Reuters) - Weight-loss drugmakers, vying to tighten the belts of Chinese consumers, are promoting obesity awareness in metro stations, exercise studios and soccer

Apple paid Ireland $17bn in taxes last year, representing 40 per cent of its worldwide total, according to filings that offer new insight into...